Industry Standard Research
The adoption of technologies is generally increasing throughout clinical trials. It took the industry some time to fully adopt and integrate EDC as the de facto standard for data collection but that has happened. ISR's data show EDC is now the data collection method of choice for the vast majority of clinical trials. We're also witnessing the maturation of other technologies in clinical trials such as online dashboards that aggregate clinical trial metrics and report on study progress; we see clinical sites relying more heavily on their electronic medical records for feasibility and patient recruitment; and we find clinical investigators and study coordinators prefer electronic patient reported outcomes (ePRO) over paper PRO.
The stage is set for further proliferation of not only ePRO, but a much broader set of eClinical service offerings and value propositions. Service providers, technology developers, and CROs need to know where their products stand and sponsors should be aware of how their partners are viewed by one of the most important cogs in the clinical development wheel: the investigative sites.
—Industry Standard Research, www.ISRreports.com/.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.